Bristol-Myers Squibb Co.

NYSE:BMY  
63.20
+0.36 (+0.57%)
Products, Regulatory

Kitov Expands Planned Phase 1/2 Clinical Trial Of CM24 In Non-Small Cell Lung Cancer

Published: 11/09/2020 13:15 GMT
Bristol-Myers Squibb Co (BMY) - Kitov Expands Planned Phase 1/2 Clinical Trial of Cm24 in Non-small Cell Lung Cancer With New Cohort to Evaluate Cm24 in Patients With Pancreatic Cancer Conducted With Bristol Myers Squibb.
With Expansion, Trial Also Planned to Evaluate Cm24 in Combination With Nivolumab in Addition to Nab-paclitaxel in Patients With Pancreatic Cancer.
Anticipate Starting Phase 1/2 Trial, Which is Being Conducted With Bristol Myers Squibb, Before End of 2020.